# Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug

> **NCT06641076** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **MoonLake Immunotherapeutics AG** · enrollment: 960 (estimated)

## Conditions studied

- Arthritis, Psoriatic

## Interventions

- **DRUG:** Sonelokimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06641076
- **Lead sponsor:** MoonLake Immunotherapeutics AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-10-15
- **Primary completion:** 2027-02-04
- **Final completion:** 2027-02-04
- **Target enrollment:** 960 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06641076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06641076, "Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT06641076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*